Copyright
©The Author(s) 2015.
World J Med Genet. Feb 27, 2015; 5(1): 1-13
Published online Feb 27, 2015. doi: 10.5496/wjmg.v5.i1.1
Published online Feb 27, 2015. doi: 10.5496/wjmg.v5.i1.1
Table 3 Suggested release tests advised by Food and Drug Administration for cell product
Category | Test | Key measurement |
Sterility | Sterility | Microbiological testing |
Mycoplasma | After pooling of cultures but before washing | |
Identity | Identity | Cell identity and assess heterogeneity |
Purity | Impurity | Residuals contaminants |
Endotoxin | Contaminants during the process | |
Potency | Specific to product | Relevant function of the cells |
Other testing | General safety | Cellular therapy products are exempt |
Viability | Generally > 70% | |
Cell number | Minimum and maximum cell number | |
Title 21 of the code of federal regulations applied to cell therapy products | ||
The tissue rules: Part 1271 | ||
The biologics requirements: Part 600 and 610 | ||
The investigational new drug requirements: Part 312 | ||
The drug manufacturing requirements: Parts 211 and 212 |
- Citation: Noh MJ, Copeland O, O’Mara M, Lee KH. Cell mediated gene therapy: A guide for doctors in the clinic. World J Med Genet 2015; 5(1): 1-13
- URL: https://www.wjgnet.com/2220-3184/full/v5/i1/1.htm
- DOI: https://dx.doi.org/10.5496/wjmg.v5.i1.1